Evidence map›Paper›PMID 29582349›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2018

Model reduction in mathematical pharmacology : Integration, reduction and linking of PBPK and systems biology models.

Thomas J Snowden, Piet H van der Graaf, Marcus J Tindall

Abstract read
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Stochastic pharmacodynamics of a heterogeneous tumour-cell population.Journal of pharmacokinetics and pharmacodynamics · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Pharmacometrics and/or Systems Pharmacology.CPT: pharmacometrics & systems pharmacology · 2019
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Thomas J SnowdenDepartment of Mathematics and Statistics, University of Reading, Reading, RG6 6AX, UK. t.snowden@reading.ac.uk.ORCID 0000-0001-9541-4043
Piet H van der GraafCertara QSP, University of Kent Innovation Centre, Canterbury, CT2 7FG, UK.
Marcus J TindallDepartment of Mathematics and Statistics, University of Reading, Reading, RG6 6AX, UK.

Funding

Engineering and Physical Sciences Research Council EP/J500501/1Engineering and Physical Sciences Research Council EP/M506606/1Engineering and Physical Sciences Research Council EP/P505682/1
6 · The paper itself

Abstract

In this paper we present a framework for the reduction and linking of physiologically based pharmacokinetic (PBPK) models with models of systems biology to describe the effects of drug administration across multiple scales. To address the issue of model complexity, we propose the reduction of each type of model separately prior to being linked. We highlight the use of balanced truncation in reducing the linear components of PBPK models, whilst proper lumping is shown to be efficient in reducing typically nonlinear systems biology type models. The overall methodology is demonstrated via two example systems; a model of bacterial chemotactic signalling in Escherichia coli and a model of extracellular regulatory kinase activation mediated via the extracellular growth factor and nerve growth factor receptor pathways. Each system is tested under the simulated administration of three hypothetical compounds; a strong base, a weak base, and an acid, mirroring the parameterisation of pindolol, midazolam, and thiopental, respectively. Our method can produce up to an 80% decrease in simulation time, allowing substantial speed-up for computationally intensive applications including parameter fitting or agent based modelling. The approach provides a straightforward means to construct simplified Quantitative Systems Pharmacology models that still provide significant insight into the mechanisms of drug action. Such a framework can potentially bridge pre-clinical and clinical modelling - providing an intermediate level of model granularity between classical, empirical approaches and mechanistic systems describing the molecular scale.

Indexed as

Escherichia coliHumansMaleModels, BiologicalReceptors, Nerve Growth FactorSignal TransductionSystems BiologyReceptors, Nerve Growth FactorMathematical pharmacologyModel reductionPBPKSystems pharmacology

Identifiers

PMID29582349
PMCPMC6061126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.